Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.

Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y.

Diagn Microbiol Infect Dis. 2011 Sep;71(1):38-45. doi: 10.1016/j.diagmicrobio.2011.05.010. Epub 2011 Jul 16.

PMID:
21763093
2.

Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW.

Clin Infect Dis. 2003 Sep 15;37(6):745-51. Epub 2003 Aug 23.

PMID:
12955633
3.

The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit.

Zaragoza R, Artero A, Camarena JJ, Sancho S, González R, Nogueira JM.

Clin Microbiol Infect. 2003 May;9(5):412-8.

4.

Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?

Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P, Harbarth S, Anderson DJ, Karchmer AW, Schwaber MJ, Carmeli Y.

Clin Infect Dis. 2009 Mar 1;48(5):580-6. doi: 10.1086/596709.

PMID:
19191643
5.

Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.

Tuon FF, Gortz LW, Rocha JL.

Braz J Infect Dis. 2012 Jul-Aug;16(4):351-6. doi: 10.1016/j.bjid.2012.06.009.

6.

Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.

Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH.

Antimicrob Agents Chemother. 2013 Mar;57(3):1270-4. doi: 10.1128/AAC.02235-12. Epub 2012 Dec 21.

7.

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH.

Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11.

8.

Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

Kim YJ, Jun YH, Kim YR, Park KG, Park YJ, Kang JY, Kim SI.

BMC Infect Dis. 2014 Mar 24;14:161. doi: 10.1186/1471-2334-14-161.

9.

Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.

Park SY, Park HJ, Moon SM, Park KH, Chong YP, Kim MN, Kim SH, Lee SO, Kim YS, Woo JH, Choi SH.

BMC Infect Dis. 2012 Nov 16;12:308. doi: 10.1186/1471-2334-12-308.

10.

Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC.

Antimicrob Agents Chemother. 2007 Oct;51(10):3510-5. Epub 2007 Jul 23.

11.

Pseudomonas aeruginosa bloodstream infections: how should we treat them?

van Delden C.

Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S71-5. Epub 2007 Aug 14. Review.

PMID:
17698326
12.

Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.

Suárez C, Peña C, Gavaldà L, Tubau F, Manzur A, Dominguez MA, Pujol M, Gudiol F, Ariza J.

Int J Infect Dis. 2010 Sep;14 Suppl 3:e73-8. doi: 10.1016/j.ijid.2009.11.019. Epub 2010 Mar 11.

13.

Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa.

Horino T, Chiba A, Kawano S, Kato T, Sato F, Maruyama Y, Nakazawa Y, Yoshikawa K, Yoshida M, Hori S.

Intern Med. 2012;51(1):59-64. Epub 2012 Jan 1.

14.

Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.

Lee CC, Lee CH, Hong MY.

Am J Emerg Med. 2012 Jul;30(6):852-60. doi: 10.1016/j.ajem.2011.05.029. Epub 2011 Aug 19.

PMID:
21855263
15.

National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.

Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, Lachish T, Wiener-Well Y, Alon D, Chowers M, Ciobotaro P, Bardenstein R, Paz A, Potasman I, Giladi M, Schechner V, Schwaber MJ, Klarfeld-Lidji S, Carmeli Y.

Antimicrob Agents Chemother. 2010 Dec;54(12):5099-104. doi: 10.1128/AAC.00565-10. Epub 2010 Sep 13.

16.

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C.

Crit Care Med. 2003 Dec;31(12):2742-51.

PMID:
14668610
17.

Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW.

Antimicrob Agents Chemother. 2010 Sep;54(9):3717-22. doi: 10.1128/AAC.00207-10. Epub 2010 Jun 28.

18.

Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.

Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases REIPI.

Antimicrob Agents Chemother. 2012 Mar;56(3):1265-72. doi: 10.1128/AAC.05991-11. Epub 2011 Dec 12.

19.

Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.

Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.

Clin Infect Dis. 2008 Mar 15;46(6):862-7. doi: 10.1086/528712.

PMID:
18279040
20.

[Effect of adequate initial antimicrobial therapy on mortality in critical patients with Pseudomonas aeruginosa bacteremia].

González AL, Leal AL, Cortés JA, Sánchez R, Barrero LI, Castillo JS, Álvarez CA.

Biomedica. 2014 Apr;34 Suppl 1:58-66. doi: 10.1590/S0120-41572014000500008. Spanish.

Supplemental Content

Support Center